Posts Shortcodes
You can show the posts with Porto Blog, Porto Recent Posts shortcodes.
Recent
Timeline
March 2026
For Up to Date News 🚨
For up-to-date news on everything Boston Harbor Angels follow us at the Boston Harbor Angels LinkedIn page.Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine
San Francisco, CA., March 30, 2026 — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $15 million grant to support the expanded clinical development of ISP-001, its lead investigational therapy for the treatment of mucopolysaccharidosis type I (MPS I), a rare and life-threatening lysosomal storage disorder. “There is no cure for MPS I, and there is a significant unmet need for therapies that...Grid
For Up to Date News 🚨
For up-to-date news on everything Boston Harbor Angels follow us at the Boston Harbor Angels LinkedIn page.Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine
San Francisco, CA., March 30, 2026 — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $15 million grant to support the expanded clinical development of ISP-001, its lead investigational therapy for the treatment of mucopolysaccharidosis type I (MPS I), a rare and life-threatening lysosomal storage disorder. “There is no cure for MPS I, and there is a significant unmet need for therapies that...GelMEDIX, Catalent Partner to Advance iPSC-Derived Cell Therapies
GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent Inc., a global contract development and manufacturing organization (CDMO), have partnered to utilize Catalent’s GMP-induced pluripotent stem cells (iPSC) and cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases. Read More>>Medium
For Up to Date News 🚨
For up-to-date news on everything Boston Harbor Angels follow us at the Boston Harbor Angels LinkedIn page.Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine
San Francisco, CA., March 30, 2026 — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $15 million grant to support the expanded clinical development of ISP-001, its lead investigational therapy for the treatment of mucopolysaccharidosis type I (MPS I), a rare and life-threatening lysosomal storage disorder. “There is no cure for MPS I, and there is a significant unmet need for therapies that...Large
30Mar
For Up to Date News 🚨
For up-to-date news on everything Boston Harbor Angels follow us at the Boston Harbor Angels LinkedIn page.
30Mar
Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine
San Francisco, CA., March 30, 2026 — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $15 million grant to support the expanded clinical development of ISP-001, its lead investigational therapy for the treatment of mucopolysaccharidosis type I (MPS I), a rare and life-threatening lysosomal storage disorder. “There is no cure for MPS I, and there is a significant unmet need for therapies that...Large Alt
30Mar
For Up to Date News 🚨
For up-to-date news on everything Boston Harbor Angels follow us at the Boston Harbor Angels LinkedIn page.
30Mar
Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine
San Francisco, CA., March 30, 2026 — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $15 million grant to support the expanded clinical development of ISP-001, its lead investigational therapy for the treatment of mucopolysaccharidosis type I (MPS I), a rare and life-threatening lysosomal storage disorder. “There is no cure for MPS I, and there is a significant unmet need for therapies that...Full
30Mar
For Up to Date News 🚨
For up-to-date news on everything Boston Harbor Angels follow us at the Boston Harbor Angels LinkedIn page.
30Mar